Related Experiment Video
Updated: Sep 28, 2026

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
DMXAA: an antivascular agent with multiple host responses
Bruce C Baguley1, Lai Ming Ching
1Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand. b.baguley@auckland.ac.nz
Purpose:
To measure host responses to the antivascular agent DMXAA (5,6-dimethylxanthenone-4-acetic acid) and to compare them with those of other antivascular agents.
Methods:
Induction of tumor necrosis was measured in s.c. murine Colon 38 carcinomas growing in normal or tumor necrosis factor (TNF) receptor-1 knockout mice. Plasma and tumor tissue TNF concentrations were measured by ELISA. Plasma concentrations of 5-hydroxyindoleacetic acid (as a measure of serotonin release) and nitrite (as a measure of nitric oxide release) were measured by high-performance liquid chromatography.
Results:
Administration of DMXAA to tumor-bearing mice increased plasma and tumor tissue-associated TNF, in addition to increasing plasma nitric oxide, distinguishing its action from that of mitotic poisons that had an antivascular action. Results from TNF receptor-1 knockout mice showed that TNF played an important role in both its antitumor action and its host toxicity. Release of serotonin occurred in response to mitotic poisons, as well as to DMXAA. CONCLUCIONS: The antivascular action of DMXAA involves in situ production in tumor tissue of a cascade of vasoactive events, including a direct effect on vascular endothelial cells and indirect vascular effects involving TNF, other cytokines, serotonin, and nitric oxide. Now that Phase I clinical trials of DMXAA are completed, the optimization of this cascade in cancer patients is a major challenge. Plasma 5-hydroxyindoleacetic acid concentrations may provide a useful surrogate marker for the antivascular effects of DMXAA and other antivascular agents.
Insights
The antivascular drug DMXAA triggers a cascade of vasoactive events in tumors, involving tumor necrosis factor (TNF) and serotonin. Measuring 5-hydroxyindoleacetic acid in plasma may serve as a marker for DMXAA
Area of Science:
- Oncology
- Pharmacology
- Immunology
Background:
- Antivascular agents are crucial in cancer therapy.
- Understanding host responses to these agents is key for optimizing treatment.
- DMXAA (5,6-dimethylxanthenone-4-acetic acid) is an antivascular agent with potential therapeutic applications.
Purpose of the Study:
- To measure host responses to the antivascular agent DMXAA.
- To compare DMXAA's host responses with those of other antivascular agents.
Main Methods:
- Tumor necrosis was induced in murine Colon 38 carcinomas.
- Tumor necrosis factor (TNF) concentrations were measured in plasma and tumor tissue.
- Serotonin and nitric oxide release were quantified using high-performance liquid chromatography.
Main Results:
- DMXAA increased plasma and tumor TNF, nitric oxide, and serotonin release.
- TNF played a significant role in DMXAA's antitumor action and host toxicity.
- DMXAA's antivascular effects involve a cascade of vasoactive events.
Conclusions:
- DMXAA's antivascular action is mediated by a complex cascade involving TNF, serotonin, and nitric oxide.
- Plasma 5-hydroxyindoleacetic acid may be a useful surrogate marker for antivascular effects.
- Optimizing this cascade in cancer patients is a critical challenge for future DMXAA therapy.
Related Concept Videos
Cholinergic Antagonists: Pharmacokinetics
Pharmacodynamic Responses: Different Types
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Vasodilators
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
